Semaglutide

BACKGROUND: Patients with overweight or obesity (OW/OB) are at increased risk for multimorbidity (≥2 obesity-related complications [ORCs]) and accompanying increases in mortality and excess costs. RESEARCH DESIGN AND METHODS: A retrospective, observa…

PURPOSE: The Inflation Reduction Act (IRA) introduced significant reforms to Medicare Part D in 2025, aiming to reduce medication costs for beneficiaries by eliminating the coverage gap ("donut hole") with a $2,000 annual out-of-pocket cap. However,…

AIMS: Young adults (aged ≤ 40 years) are underrepresented in clinical trials that investigate interventions for those living with Type 2 diabetes (T2D). This study evaluated the efficacy of semaglutide treatment in young adults with T2D by examining…

BACKGROUND: Obesity is linked to cardiometabolic risk, and semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising option for weight and metabolic control. This systematic review and meta-analysis evaluated the effects of…

Metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of metabolic syndrome, has emerged as the leading cause of chronic liver disease worldwide. Its global prevalence estimated at 38% between 2016-2019, represen…

OBJECTIVE: Arteriovenous fistulae (AVF) are necessary for hemodialysis in patients with end-stage kidney disease (ESKD), but are frequently complicated by thrombosis, stenosis, and need for revision. Glucagon-like peptide-1 receptor agonists (GLP-1RA…

The existing literature on the effects of semaglutide in people with HIV (PWH) and diabetes mellitus remains limited. In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observation…

BACKGROUND AND AIMS: The burden of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis is rapidly rising globally. There are several therapeutic agents under clinical development for the treatment of cirrhosis due to MASH; however, thei…

AIMS: In SURMOUNT-5, tirzepatide led to greater body weight (BW) reduction versus semaglutide in adults with obesity without T2D. Health-related quality of life (HRQoL) with tirzepatide versus semaglutide in SURMOUNT-5 was evaluated. MATERIALS AND ME…

BACKGROUND: Coronary microembolization (CME) is the major leading cause of perioperative myocardial injury during coronary revascularization. Semaglutide exerts multiple protective biological activities, but its cardioprotective effects on CME remain…

INTRODUCTION: Over the past 2 decades, treatment for type 2 diabetes (T2D) has evolved with the introduction of medications that offer greater simplicity. The Simplicity of Diabetes Treatment Questionnaire (Sim-Q™) was developed to assess the simplic…

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly prescribed for type 2 diabetes and obesity, have demonstrated potential anti-inflammatory and immunomodulatory effects that may be beneficial in chronic inflammatory skin conditions such…

This study aimed to investigate the anti-atherosclerotic properties of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, in comparison with semaglutide, a selective GLP-1 receptor…

Liquid buffer pH influences the peptide higher order structure (HOS), including oligomerization, with important implications for peptide drug formulation development and stability control. Although dynamic light scattering (DLS) and diffusion-ordered…

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease now targeted by new pharmacotherapies, including the thyroid hormone receptor beta (THR-β) agonist resmetirom, glucagon-like peptide-1 (GLP-1) receptor agonists (s…

Metabolic dysfunction associated steatotic liver disease (MASLD) affects nearly one-third of adults worldwide, particularly among individuals with obesity or type 2 diabetes, and in 10-30% progresses to metabolic dysfunction associated steatohepatiti…